Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA).

Full DD Report for DRNA

You must become a subscriber to view this report.


Recent News from (NASDAQ: DRNA)

After Hours Gainers / Losers (05/17/2018)
Top gainers:   QTNT   +12.1% .  AFSI +6.1% . EIGR   +3.5% . DRNA +3.0% . TIVO   +2.0% . More news on: Quotient Limited, AmTrust Financial Services, Inc., Eiger BioPharmaceuticals, Inc., Stocks on the move, , News on ETFs, Read more ...
Source: SeekingAlpha
Date: May, 17 2018 17:35
Dicerna Pharmaceuticals' (DRNA) CEO Douglas Fambrough on Q1 2018 Results - Earnings Call Transcript
Dicerna Pharmaceuticals, Inc. (DRNA) Q1 2018 Earnings Conference Call May 14, 2018, 04:30 PM ET Executives Douglas Fambrough - Co-Founder, CEO, President John Green - CFO Ralf Rosskamp - Chief Medical Officer Bob Brown - Chief Scientific Officer Analysts Jonathan Miller -...
Source: SeekingAlpha
Date: May, 14 2018 21:00
Dicerna Pharmaceuticals beats by $0.08, misses on revenue
Dicerna Pharmaceuticals (NASDAQ: DRNA ): Q1 EPS of -$0.30 beats by $0.08 . More news on: Dicerna Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Source: SeekingAlpha
Date: May, 14 2018 16:10
Dicerna Reports First Quarter 2018 Financial and Operating Results and Provides Corporate Update
Management to Host Conference Call Today at 4:30 p.m. ET Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today reported financial and operating results for the first quarter ended March 31, 2018....
Source: Business Wire
Date: May, 14 2018 16:05
Institutional Top Ideas Series: Ra Capital Management
In the last entry of this series we took a look at top ideas from Orbimed Advisors, a large fund in the midst of a leadership transition which avoids outsized bets (over 5% weighting) yet still has posted decent returns. Going forward, I hope to continue to delve into the portfolios of su...
Source: SeekingAlpha
Date: May, 10 2018 02:04
Dicerna to Report First Quarter 2018 Financial Results and Host Conference Call on May 14, 2018
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its first quarter 2018 financial results after market close on Monday, May 14, 2018. Management will hos...
Source: Business Wire
Date: May, 07 2018 07:30
Eidos Therapeutics commences mid-stage study of lead drug in ATTR
Privately held Eidos Therapeutics announces that the first patient has been dosed in a Phase 2 clinical trial assessing lead candidate AG10 in patients with symptomatic transthyretin amyloidosis (ATTR) cardiomyopathy. More news on: Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals...
Source: SeekingAlpha
Date: May, 03 2018 09:55
Cirius Therapeutics completes enrollment in mid-stage study of lead candidate in NASH
Privately held Cirius Therapeutics announces that it has reached the enrollment target in a Phase 2b clinical trial, EMMINENCE , assessing lead candidate MSDC-0602K in patients with NASH and liver fibrosis. More news on: Conatus Pharmaceuticals, Galectin Therapeutics, Inc., Navidea Bi...
Source: SeekingAlpha
Date: May, 02 2018 10:47
Does Dicerna's Settlement Agreement With Alnylam Make It A Buy?
This past Friday, shares of Dicerna Pharmaceuticals ( DRNA ) closed the day higher by 17.86% to $12.01 per share after it had reported a settlement agreement was achieved between it and Alnylam Pharmaceuticals ( ALNY ). This is a good outcome for Dicerna, because now it can focus on it...
Source: SeekingAlpha
Date: April, 23 2018 02:48
Midday Gainers / Losers (04/20/2018)
Gainers:   DRNA +38% . LLNW +22% . ERIC +17% . NAP +16% . FFKT +16% . CALI +12% . CIDM +12% . MYO +10% . OFG +10% . SSW +9% . More news on: Dicerna Pharmaceuticals, Inc., Limelight Networks, Inc., LM Ericsson Telephone Company, Stocks on the move, , ...
Source: SeekingAlpha
Date: April, 20 2018 12:55

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-1715.0314.8615.2914.71191,001
2018-08-1614.6215.0515.1914.33423,333
2018-08-1515.4714.5416.31514.10735,437
2018-08-1414.9014.8815.0414.72217,745
2018-08-1314.6514.6715.13514.33223,240

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-1725,54137,36368.3591Short
2018-08-1672,989117,68462.0212Short
2018-08-15133,195300,94844.2585Short
2018-08-14119,194131,64790.5406Short
2018-08-1333,01168,34948.2977Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on DRNA.


About Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA)

Logo for Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA)

Not available

 

Contact Information

     

     

    Current Share Structure

       


      Recent Filings from (NASDAQ: DRNA)

      Simplified registration form
      Filing Type: S-3Filing Source: edgar
      Filing Date: May, 17 2018
      Quarterly report with a continuing view of a company's financial position
      Filing Type: 10-QFiling Source: edgar
      Filing Date: May, 14 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: May, 14 2018
      Prospectus filed under Rule 424(b)(3)
      Filing Type: 424B3Filing Source: edgar
      Filing Date: May, 11 2018
      Pre-effective amendment to an S-3 filing
      Filing Type: S-3/AFiling Source: edgar
      Filing Date: May, 04 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 26 2018
      Official notification to shareholders of matters to be brought to a vote (Proxy)
      Filing Type: DEF 14AFiling Source: edgar
      Filing Date: April, 26 2018
      Additional proxy soliciting materials - definitive
      Filing Type: DEFA14AFiling Source: edgar
      Filing Date: April, 26 2018
      Report of unscheduled material events or corporate changes.
      Filing Type: 8-KFiling Source: edgar
      Filing Date: April, 23 2018
      Filing Type: CT ORDERFiling Source: edgar
      Filing Date: April, 06 2018

       

       


      Daily Technical Chart for (NASDAQ: DRNA)

      Daily Technical Chart for (NASDAQ: DRNA)


      Stay tuned for daily updates and more on (NASDAQ: DRNA)

      It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

      More to come on (NASDAQ: DRNA)

      Do your DD and if you choose, be ready to go!


       

      The Research: All source information contained in this email is from the public sources mentioned below.

       

       
       

      Thank you

      DD Report
      @DDReports

       

       


      Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in DRNA is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of DRNA and does not buy, sell, or trade any shares of DRNA. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/